Vireo Growth Reports 317% Q4 Revenue Surge, Strong EBITDA, and Active M&A

summarizeSummary

Vireo Growth Inc. announced robust Q4 2025 financial results, with GAAP revenue surging 317.7% year-over-year and Adjusted EBITDA increasing 347%, alongside a strong cash position and ongoing strategic acquisitions.

check_boxKey Events · Earnings and Guidance · VREOF

• Record Q4 Revenue Growth

  GAAP revenue for Q4 2025 increased 317.7% year-over-year to $104.5 million, primarily driven by recent M&A transactions. Pro forma same-store sales increased 22% year-over-year.

• Significant Adjusted EBITDA Increase

  Adjusted EBITDA for Q4 2025 surged 347.0% year-over-year to $29.5 million, with an Adjusted EBITDA Margin of 28.2%.

• Strong Liquidity Position

  The company closed the fourth quarter with $122.5 million in cash, providing substantial liquidity for operations and future growth initiatives.

• Aggressive M&A Strategy Continues

  Vireo announced pending acquisitions of Eaze (estimated $47 million in shares) and PharmaCann retail assets (estimated $49 million in shares), along with a non-binding MOU for The Hawthorne Gardening Company, all expected to close in the first half of 2026.

auto_awesomeAnalysis · VREOF · Life Sciences

Vireo Growth Inc. delivered exceptionally strong fourth-quarter results, driven primarily by recently closed M&A transactions. The substantial year-over-year growth in both GAAP revenue and Adjusted EBITDA indicates successful integration and expansion. The company's robust cash position provides a solid foundation for continued operations and its stated strategy of remaining acquisitive. The ongoing pipeline of significant pending acquisitions, such as Eaze and PharmaCann retail assets, signals aggressive growth ambitions, though these will involve share consideration and potential dilution. Investors should monitor the successful closing and integration of these future acquisitions and their impact on profitability.